Sign in
Welcome! Log into your account
Forgot your password? Get helpPrivacy PolicyPassword recovery
Recover your password
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology NewsHomeMultimediaGEN LiveGenome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
Credit: DrAfter123/Getty Images
Laura Sepp-Lorenzino, PhD
Former CSO
Intellia Therapeutics
Panelist
Laura Sepp-Lorenzino, PhD
Laura Sepp-Lorenzino, PhD, is scientific advisor and former chief scientific officer at Intellia Therapeutics, a clinical-stage genome editing company developing potential curative CRISPR-based medicines. Previously, she was vice president and head of Nucleic Acid Therapies at Vertex Pharmaceuticals and part of External Innovation. She also held roles at Alnylam Pharmaceuticals and Merck & Co. In addition, she currently serves as the director of the American Society of Gene and Cell Therapy (ASGCT).
Shengdar Tsai, PhD
Associate Member,
Department of Hematology
St. Jude Children’s Research Hospital
Panelist
Shengdar Tsai, PhD
Shengdar Tsai, PhD, is an associate member in the Department of Hematology at St. Jude Children’s Research Hospital. His lab’s research focuses on developing genome editing technologies for therapeutics, with a special interest in editing human HSCs for treatment of hemoglobinopathies such as sickle cell disease and T cells for cancer immunotherapy. In 2020, he was chosen as one of the American Society for Gene and Cell Therapy (ASGCT) Outstanding New Investigators.
Broadcast Date:Wednesday, July 15, 2026
- Time:09:00 PDT, 12:00 EDT, 18:00 CET
CRISPR is now a household term. Stories of genome editing therapies like Casgevy and Baby KJ have been headlines in our inboxes for years. Despite those cases, and the optimism they bring, genome editing has had significant challenges moving into the clinic.
This GEN Live show brings together a panel of leading experts to break down the latest advances, innovations, and challenges shaping genome editing. The discussion covers a lot of bases: CRISPR breakthroughs, emerging gene editing platforms, clinical trial milestones, regulatory shifts, access, off-target effects and safety considerations, and the growing role of large-scale population genomics in guiding precision therapies. Watch the event to learn more from our expert panelists and hear the questions submitted by our audience during the discussion.
Produced with support from:
Copyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
MORE STORIES
